RS50291B - Novi galenski oblik molsidomina za oralnu upotrebu sa produženim delovanjem - Google Patents
Novi galenski oblik molsidomina za oralnu upotrebu sa produženim delovanjemInfo
- Publication number
- RS50291B RS50291B YUP-622/02A YUP62202A RS50291B RS 50291 B RS50291 B RS 50291B YU P62202 A YUP62202 A YU P62202A RS 50291 B RS50291 B RS 50291B
- Authority
- RS
- Serbia
- Prior art keywords
- molsidomine
- hours
- released
- oral administration
- prolonged release
- Prior art date
Links
- XLFWDASMENKTKL-UHFFFAOYSA-N molsidomine Chemical compound O1C(N=C([O-])OCC)=C[N+](N2CCOCC2)=N1 XLFWDASMENKTKL-UHFFFAOYSA-N 0.000 title abstract 10
- 229960004027 molsidomine Drugs 0.000 title abstract 10
- 230000002035 prolonged effect Effects 0.000 title 1
- NCGICGYLBXGBGN-UHFFFAOYSA-N 3-morpholin-4-yl-1-oxa-3-azonia-2-azanidacyclopent-3-en-5-imine;hydrochloride Chemical compound Cl.[N-]1OC(=N)C=[N+]1N1CCOCC1 NCGICGYLBXGBGN-UHFFFAOYSA-N 0.000 abstract 1
- 230000001419 dependent effect Effects 0.000 abstract 1
- 238000004090 dissolution Methods 0.000 abstract 1
- 238000000338 in vitro Methods 0.000 abstract 1
- 238000001727 in vivo Methods 0.000 abstract 1
- 239000002207 metabolite Substances 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
- 239000007787 solid Substances 0.000 abstract 1
- 238000013268 sustained release Methods 0.000 abstract 1
- 239000012730 sustained-release form Substances 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
- A61K9/2086—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
Landscapes
- Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- Pulmonology (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Vascular Medicine (AREA)
- Urology & Nephrology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Hydrogenated Pyridines (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Abstract
Čvrsti oralni galenski oblik molsidomina sa produženim oslobađanjem, naznačen time što sadrži terapeutski efikasnu količinu molsidomina ili jedan od njegovih aktivnih metabolita, odabranih od jedinjenja SIN-1 i SIN-1A i što ima in vitro brzinu rastvaranja [merenu spektrofotometrijski na 286 ili 311 nm prema metodi koja je opisana u Pharmacopee Europeenne, 3-će izdanje (ili U.S.P.XXIV) na 50 rpm (obrtaja/min) u 500ml u 0,1 N HC1, na 37°C] od : -15 do 25 % molsidomina oslobođenog nakon 1 sat - 20 do 35 % molsidomina oslobođenog posle 2 sata - 50 do 65 % molsidomina oslobođenog posle 6 sati - 75 do 95 % molsidomina oslobođenog posle 12 sati - > 85 % molsidomina oslobođenog posle 18 sati - > 90 % molsidomina oslobođenog posle 24 sata gde se pik molsidomina u plazmi postignut in vivo javlja za 2,5 do 5 sati, najčešće za 3 do 4 sata, posle administracije naznačenog oblika , i ima vrednosti između 25 i 40 ng/ml plazme. Prijava sadrži 11 zavisnih zahteva
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
FR0002307A FR2805462B1 (fr) | 2000-02-24 | 2000-02-24 | Nouvelle forme galenique orale a liberation prolongee de la molsidomine |
Publications (2)
Publication Number | Publication Date |
---|---|
YU62202A YU62202A (sh) | 2006-01-16 |
RS50291B true RS50291B (sr) | 2009-09-08 |
Family
ID=8847342
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
YUP-622/02A RS50291B (sr) | 2000-02-24 | 2001-02-22 | Novi galenski oblik molsidomina za oralnu upotrebu sa produženim delovanjem |
Country Status (36)
Country | Link |
---|---|
US (1) | US7767227B2 (sr) |
EP (1) | EP1265614B1 (sr) |
JP (1) | JP4945043B2 (sr) |
KR (1) | KR100814191B1 (sr) |
CN (1) | CN100396284C (sr) |
AT (1) | ATE296632T1 (sr) |
AU (2) | AU4065301A (sr) |
BE (1) | BE1013487A3 (sr) |
BG (1) | BG66111B1 (sr) |
BR (1) | BRPI0108041B8 (sr) |
CA (1) | CA2400886C (sr) |
CZ (1) | CZ301993B6 (sr) |
DE (1) | DE60111196T2 (sr) |
DZ (1) | DZ3273A1 (sr) |
EE (1) | EE05098B1 (sr) |
ES (1) | ES2241803T3 (sr) |
FR (1) | FR2805462B1 (sr) |
HK (1) | HK1050138B (sr) |
HR (1) | HRP20020692B1 (sr) |
HU (1) | HU229799B1 (sr) |
IL (2) | IL151205A0 (sr) |
IS (1) | IS2446B (sr) |
MA (1) | MA25576A1 (sr) |
MD (1) | MD3119C2 (sr) |
MX (1) | MXPA02008262A (sr) |
NO (1) | NO329495B1 (sr) |
NZ (1) | NZ520691A (sr) |
OA (1) | OA12183A (sr) |
PL (1) | PL201631B1 (sr) |
PT (1) | PT1265614E (sr) |
RS (1) | RS50291B (sr) |
RU (1) | RU2263506C2 (sr) |
SK (1) | SK286313B6 (sr) |
UA (1) | UA73972C2 (sr) |
WO (1) | WO2001062256A1 (sr) |
ZA (1) | ZA200206042B (sr) |
Families Citing this family (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
FR2805462B1 (fr) * | 2000-02-24 | 2003-08-15 | Therabel Res | Nouvelle forme galenique orale a liberation prolongee de la molsidomine |
US7803402B2 (en) * | 2002-07-06 | 2010-09-28 | Sanjeev Khandelwal | Pharmaceutical preparations |
FR2868314B1 (fr) * | 2004-04-05 | 2008-10-24 | Therabel Pharmaceuticals Ltd | Nouvelle utilisation therapeutique de la molsidomine et de ses sels pharmaceutiquement acceptables |
EP2468269A1 (en) | 2010-11-26 | 2012-06-27 | Universitätsklinikum Münster | Nitric oxide donors in therapy of nitric oxide deficiency-induced disturbances of cerebral microcirculation |
BE1028879B1 (fr) | 2020-12-11 | 2022-07-12 | Europharmaceuticals | Comprimé à libération prolongée de la molsidomine |
Family Cites Families (16)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE3522191A1 (de) * | 1985-06-21 | 1987-01-15 | Cassella Ag | Photostabilisierung von sydnoniminen |
CN1006522B (zh) * | 1986-04-30 | 1990-01-24 | 田道制药有限公司 | 缓放性制剂的制备方法 |
HU210921B (en) * | 1990-03-28 | 1995-09-28 | Chinoin Gyogyszer Es Vegyeszet | Process for preparing inclusion complexes of n-ethoxycarbonyl-3-morpholino-sydnonimine formed with cyclodextrines and pharmaceutical compositions containing them |
HU211648A9 (en) * | 1990-03-28 | 1995-12-28 | Chinoin Gyogyszer Es Vegyeszet | Inclusion complexes of 3-morpholino-sydnonimine or its salts or its tautomer isomer, process for the preparation thereof, and pharmaceutical compositions containing the same |
DE4140192C2 (de) * | 1991-12-05 | 1996-02-29 | Alfatec Pharma Gmbh | Sol-gesteuerte Thermokolloidmatrix auf Gelatinebasis für perorale Retardformen |
DE59408793D1 (de) * | 1993-05-11 | 1999-11-11 | Hoechst Ag | Galenische Zubereitungen von Molsidomin |
EP0707465A4 (en) * | 1993-07-08 | 1997-04-16 | Cygnus Therapeutic Systems | MONOLITHIC MATRIX TRANSDERMAL DELIVERY SYSTEM |
IT1266565B1 (it) * | 1993-07-22 | 1997-01-09 | Ct Lab Farm Srl | Composizioni farmaceutiche a rilascio controllato a base di uno o piu' sali farmaceuticamente accettabili dell'acido gamma-idrossi-butirrico. |
HU218280B (en) * | 1994-04-26 | 2000-07-28 | Cyclodextrin inclusion complexes containing sin-1a which are stable intheir solid state, process for their preparation and pharmaceutical compositions containing the comlexes | |
DE4443105C2 (de) * | 1994-12-03 | 1997-03-13 | Hoechst Ag | Verfahren zur Herstellung Molsidomin-haltiger Tabletten |
JPH09114680A (ja) * | 1995-10-19 | 1997-05-02 | Fuji Xerox Co Ltd | シーケンス制御装置 |
IT1282576B1 (it) * | 1996-02-06 | 1998-03-31 | Jagotec Ag | Compressa farmaceutica atta a cedere la sostanza attiva in tempi successivi e predeterminabili |
PE57198A1 (es) * | 1996-03-25 | 1998-10-10 | American Home Prod | Formula de liberacion prolongada |
DE69828635T2 (de) * | 1997-09-19 | 2005-06-16 | Shire Laboratories, Inc. | Feste lösungskügelchen |
FR2775188B1 (fr) * | 1998-02-23 | 2001-03-09 | Lipha | Forme galenique a liberation immediate ou liberation prolongee administrable par voie orale comprenant un agent promoteur d'absorption et utilisation de cet agent promoteur d'absorption |
FR2805462B1 (fr) * | 2000-02-24 | 2003-08-15 | Therabel Res | Nouvelle forme galenique orale a liberation prolongee de la molsidomine |
-
2000
- 2000-02-24 FR FR0002307A patent/FR2805462B1/fr not_active Expired - Lifetime
-
2001
- 2001-02-22 NZ NZ520691A patent/NZ520691A/en not_active IP Right Cessation
- 2001-02-22 WO PCT/EP2001/002055 patent/WO2001062256A1/fr active IP Right Grant
- 2001-02-22 CN CNB018052592A patent/CN100396284C/zh not_active Expired - Lifetime
- 2001-02-22 JP JP2001561321A patent/JP4945043B2/ja not_active Expired - Lifetime
- 2001-02-22 AU AU4065301A patent/AU4065301A/xx active Pending
- 2001-02-22 BE BE2001/0121A patent/BE1013487A3/fr not_active IP Right Cessation
- 2001-02-22 EE EEP200200472A patent/EE05098B1/xx unknown
- 2001-02-22 DZ DZ013273A patent/DZ3273A1/fr active
- 2001-02-22 DE DE60111196T patent/DE60111196T2/de not_active Expired - Lifetime
- 2001-02-22 SK SK1220-2002A patent/SK286313B6/sk not_active IP Right Cessation
- 2001-02-22 BR BRPI0108041A patent/BRPI0108041B8/pt not_active IP Right Cessation
- 2001-02-22 AU AU2001240653A patent/AU2001240653B9/en not_active Expired
- 2001-02-22 IL IL15120501A patent/IL151205A0/xx active IP Right Grant
- 2001-02-22 KR KR1020027010441A patent/KR100814191B1/ko active IP Right Grant
- 2001-02-22 PL PL357550A patent/PL201631B1/pl unknown
- 2001-02-22 PT PT01911692T patent/PT1265614E/pt unknown
- 2001-02-22 HU HU0300607A patent/HU229799B1/hu unknown
- 2001-02-22 RS YUP-622/02A patent/RS50291B/sr unknown
- 2001-02-22 AT AT01911692T patent/ATE296632T1/de active
- 2001-02-22 OA OA1200200258A patent/OA12183A/fr unknown
- 2001-02-22 ES ES01911692T patent/ES2241803T3/es not_active Expired - Lifetime
- 2001-02-22 US US10/182,718 patent/US7767227B2/en not_active Expired - Fee Related
- 2001-02-22 EP EP01911692A patent/EP1265614B1/fr not_active Expired - Lifetime
- 2001-02-22 UA UA2002086983A patent/UA73972C2/uk unknown
- 2001-02-22 RU RU2002121503/15A patent/RU2263506C2/ru active
- 2001-02-22 CZ CZ20022876A patent/CZ301993B6/cs not_active IP Right Cessation
- 2001-02-22 MX MXPA02008262A patent/MXPA02008262A/es active IP Right Grant
- 2001-02-22 CA CA2400886A patent/CA2400886C/fr not_active Expired - Lifetime
- 2001-02-22 MD MDA20020212A patent/MD3119C2/ro active IP Right Grant
-
2002
- 2002-07-29 ZA ZA200206042A patent/ZA200206042B/xx unknown
- 2002-08-06 MA MA26765A patent/MA25576A1/fr unknown
- 2002-08-12 IL IL151205A patent/IL151205A/en unknown
- 2002-08-14 IS IS6504A patent/IS2446B/is unknown
- 2002-08-22 BG BG107027A patent/BG66111B1/bg unknown
- 2002-08-22 HR HR20020692A patent/HRP20020692B1/xx not_active IP Right Cessation
- 2002-08-23 NO NO20024043A patent/NO329495B1/no not_active IP Right Cessation
-
2003
- 2003-03-27 HK HK03102218.9A patent/HK1050138B/zh not_active IP Right Cessation
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
RS50924B (sr) | Oralni dozni oblici propiverina ili njegovih farmaceutski prihvatljivih soli sa produženim oslobađanjem aktivne materije | |
NO20043913L (no) | Blandinger med modifisert frigjoring av i det minste en form av tramadol | |
CA2346001A1 (en) | Controlled release nanoparticulate compositions | |
ATE333265T1 (de) | Oral anzuwendende schnell zerfallende feste darreichungsformen | |
HUP0203204A2 (hu) | Orális adagolási forma | |
AU3104301A (en) | Compositions and methods to effect the release profile in the transdermal administration of active agents | |
AU2001263229A1 (en) | Compositions and methods for administration of pharmacologically active compounds | |
WO2007048219A3 (en) | Sustained drug release composition | |
BR9914251A (pt) | Formulações orais de liberação sustentada | |
HUP0101512A2 (hu) | Adhéziós mikrogyöngy hatóanyag-adagoló készítmény, eljárás az előállítására és a készítményt tartalmazó eszköz | |
SG145690A1 (en) | Solid pharmaceutical dosage form comprising an hiv protease inhibitor solid dispersion | |
MX2008000099A (es) | Composiciones farmaceuticas de liberacion modificada novedosas, y procedimiento de preparacion de dichas composiciones. | |
ID28510A (id) | Formulasi oral yang baru untuk agonis atau antagonis 5-ht4 | |
RS50291B (sr) | Novi galenski oblik molsidomina za oralnu upotrebu sa produženim delovanjem | |
WO2006123360A3 (en) | Microspheres containing octreotide acetate | |
BR0206960A (pt) | Composição farmacêutica oral, e, uso de um polìmero de ftalato de hidroxipropilmetilcelulose | |
DE60112578D1 (de) | Pharmazeutische diclofenac-verbindung basierend auf vitamin e, papain und hyaluronidase | |
AU2003232535A1 (en) | "soluble stable pharmaceutical composition for the administration of hiv protease inhibitors and a process for the preparation of concentrated pharmaceutical compositions for the administration of hiv protease inhibitors." | |
RS54791B1 (sr) | Oralni sastav molsidomina sa produženim oslobađanjem za aterosklerozu | |
CR6300A (es) | Nueva formulacion oral |